Baebies, Inc.

Baebies, Inc., a Durham, North Carolina–based small business medical diagnostic manufacturer, develops and delivers digital microfluidic testing platforms and point-of-care diagnostic devices to federal health agencies as a prime contractor under Total Small Business set-asides (97% of recent awards). The company specializes in rapid, multiplexed infectious disease diagnostics, trauma and coagulation assessment platforms, and pediatric testing solutions, with recent work focused on HIV assays, sexually transmitted infection viability detection, and near-patient coagulation monitoring systems for critically ill patients.

Baebies' customer base concentrates heavily in the National Institutes of Health ecosystem. The top five funding agencies account for 82% of recent awards by count. The National Institute of Child Health and Human Development leads by award volume (11 awards), followed by the National Institute of Allergy and Infectious Diseases (6 awards, $8.7 million combined potential value), the National Heart Lung and Blood Institute (5 awards), the Defense Health Agency (2 awards, $1.5 million combined potential value), and the CDC (1 award, $243 thousand). NIAID dominates the potential-value ranking at $8.7 million across six awards. Recent representative work includes a $2.299 million NIAID definitive contract awarded September 1, 2025, for development of a rapid, quantitative HIV-1 assay for viral load self-monitoring (completion August 31, 2028); a $2.3 million NIAID contract from August 2023 for a multifunctional point-of-care platform to differentiate HIV infection from vaccine-induced seropositivity (completion October 31, 2027); a $1.299 million Defense Health Agency definitive contract awarded June 10, 2026, for a user-friendly, wide multiplexing device for flexible diagnostics (completion October 9, 2028); and a $749.96 thousand Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response contract from June 2023 for a multifunctional analyzer for point-of-need testing by clinic and home use.

Baebies operates primarily as a prime contractor delivering directly with no named subcontractors across SCI-reportable service contracts. SCI-reported invoicing totaled $3 million across fiscal years 2022 through 2025, with delivery scaling from 0.9 FTEs in FY2022 to 4.1 FTEs in FY2024 and 2.1 FTEs in FY2025, all work performed in-house. On federal services contracts captured in SCI, government-paid hourly rates ranged from a median around $147/hr to a 90th percentile of roughly $775/hr, reflecting a mix of technical development labor and senior research personnel. The vendor holds one sub-award position as a sub-recipient on a Northwestern University grant for the Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases, awarded April 8, 2026.

Activity has been episodic over the past five years—one award in 2022, three in 2023, three in 2024, two in 2025, and two in 2026 to date—with six awards (combined potential value $8.2 million) reaching ultimate completion within the next twenty-four months and facing recompete. The vendor's primary capability footprint sits in SBIR Phase I and Phase II R&D contracts and project grants focused on infectious disease diagnostics, pediatric testing, and point-of-care platforms, with combined federal potential value of $11.2 million across 33 total awards but combined obligated dollars of $74.8 million (665% of potential value), indicating substantial performance delivery on earlier-year awards that have matured through completion.